Sign In
Buy PODD
$162.06
+0.780 (+0.484%)
At Close: Jul 13, 2026
Is a Surprise Coming for Insulet (PODD) This Earnings Season?
12:15pm, Wednesday, 03'rd Nov 2021
Insulet (PODD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Insulet: Heroic Assumptions Required
09:33am, Friday, 29'th Oct 2021
Insulet share price appears to have raced too high, providing outstanding historical returns but little margin for future growth. Insulet requires some heroic assumptions on revenue growth and unit co
4 Medical Products Stocks Poised to Beat This Earnings Season
12:13pm, Thursday, 28'th Oct 2021
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use
01:47pm, Thursday, 30'th Sep 2021
Insulet Corporation (NASDAQ: PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System. Omnipod 5 is a tubeless, wearable system that continuo
Insulet's Omnipod® 5 Pivotal Study Extension Data Shows Significant Improvements in Glycemic Control With One Year of Use
07:30am, Thursday, 30'th Sep 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has presented po
Insulet to Announce Third Quarter 2021 Financial Results on November 4, 2021
04:01pm, Wednesday, 29'th Sep 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Here's Why You Should Retain Insulet (PODD) Stock for Now
11:30am, Friday, 24'th Sep 2021
Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).
Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure
12:30pm, Tuesday, 07'th Sep 2021
Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.
Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev
11:25am, Tuesday, 17'th Aug 2021
Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.
FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps
03:01pm, Monday, 16'th Aug 2021
The FDA has approved the use of Eli Lilly And Co's (NYSE:LLY) Lyumjev (insulin lispro-aabc injection) 100 units/mL with Insulet Corporation's (NASDAQ:PODD) insulin management systems. Lyumjev, a
Insulet Introduces Omnipod DASH® System at Australasian Diabetes Congress
05:04pm, Wednesday, 11'th Aug 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented
Insulet Corporation (PODD) CEO Shacey Petrovic on Q2 2021 Results - Earnings Call Transcript
02:42am, Friday, 06'th Aug 2021
Insulet Corporation (PODD) CEO Shacey Petrovic on Q2 2021 Results - Earnings Call Transcript
Insulet (PODD) Q2 Earnings Lag Estimates
07:01pm, Thursday, 05'th Aug 2021
Insulet (PODD) delivered earnings and revenue surprises of -16.67% and 2.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year
04:01pm, Thursday, 05'th Aug 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain
10:41pm, Saturday, 31'st Jul 2021
Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic.
